Fear of disease progression and relapse in multiple sclerosis: a systematic scoping review
Frontiers in Psychiatry · 12.11.2025 · 16
DOI: 10.3389/fpsyt.2025.1680781 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Psychiatry, online erschienen am 12.11.2025. Verfasst von Arashk Mallahzadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Multiple sclerosis (MS) is a chronic disease of the central nervous system, most commonly affecting individuals in early adulthood. Uncertainty about future relapses and accumulating disability may lead to significant psychological distress, contributing to reduced quality of life.
Objective
This systematic scoping review aimed to synthesize current evidence on the prevalence, determinants, and consequences of fear of relapse and disease progression in people living with MS.
Method
The current systematic scoping review followed PRISMA-ScR guidelines. PubMed, Scopus, and Web of Science were searched from inception until October 6 th . Original, English-language studies investigating fear of disease progression or relapse among people with multiple sclerosis were included, without restrictions on age, gender, disease stage, or study design. Data items were collected, and a quality assessment was conducted.
Results
Our search yielded 43 studies, of which 13 met the eligibility criteria. Nine studies utilized the fear of relapse scale and the remaining four used the fear of progression questionnaire. Fear of progression among MS patients ranged from minimal to severe, with concerns centered on losing independence, relying on external help, and potential medication side effects. In relapsing-remitting MS, fear was particularly associated with uncertainty about disease course, potential disability, and worsening fatigue. Increased fear of relapse and progression was strongly associated with higher levels of fatigue, depression, stress, health anxiety, and lower quality of life.
Conclusion
Fear of relapse and progression is common and significantly impacts the lives of people with MS. Future research should focus on evaluating and implementing tailored interventions — including psychological support, educational initiatives, and coping-based strategies — to help patients manage these fears.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Student Research Committee, Bushehr University of Medical Sciences, Bushehr, Iran.
- Department of Physical Therapy and Kinesiology, University of Massachusetts Lowell, Lowell, MA, United States.
- Department of Neurology, Epilepsy Center Frankfurt Rhein-Main, University Medicine Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
- Department of Psychology, University of Bath, Bath, United Kingdom.
Zitieren
APA
Mallahzadeh, A., Fereydoonnezhad, T., Gauthier, L. V., Farjoud Kouhanjani, M., Hosseinizadeh, S., & Khatibi, A. (2025). Fear of disease progression and relapse in multiple sclerosis: a systematic scoping review. Frontiers in Psychiatry, 16. https://doi.org/10.3389/fpsyt.2025.1680781
Vancouver
Mallahzadeh A, Fereydoonnezhad T, Gauthier LV, Farjoud Kouhanjani M, Hosseinizadeh S, Khatibi A. Fear of disease progression and relapse in multiple sclerosis: a systematic scoping review. Frontiers in Psychiatry. 2025;16. doi:10.3389/fpsyt.2025.1680781
BibTeX
@article{Mallahzadeh2025,
author = {Mallahzadeh, Arashk and Fereydoonnezhad, Tahereh and Gauthier, Lynne V and Farjoud Kouhanjani, Mohsen and Hosseinizadeh, Shima and Khatibi, Ali},
title = {Fear of disease progression and relapse in multiple sclerosis: a systematic scoping review},
journal = {Frontiers in Psychiatry},
year = {2025},
volume = {16},
doi = {10.3389/fpsyt.2025.1680781}
}
EUVIMED